Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

1.9K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.9K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

2.0K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.0K
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

6.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.8K
Inflammation01:38

Inflammation

64.6K
Overview
64.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Mechanisms Governing Peptide Nanodisc Assembly and Stability.

bioRxiv : the preprint server for biology·2026
Same author

Peptide nanodiscs: Versatile platforms for membrane protein functional reconstitution and structural studies: A review.

International journal of biological macromolecules·2025
Same author

Bifunctional nanodisc platforms for studies on self-assembly and amyloid fibrillation.

Chemical communications (Cambridge, England)·2025
Same author

Characterization of nanodisc-forming peptides for membrane protein studies.

Journal of colloid and interface science·2023
Same author

Peptides as Therapeutic Agents for Atherosclerosis.

Methods in molecular biology (Clifton, N.J.)·2022
Same author

Nanodisc reconstitution of flavin mononucleotide binding domain of cytochrome-P450-reductase enables high-resolution NMR probing.

Chemical communications (Cambridge, England)·2021

Related Experiment Video

Updated: Apr 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Recent developments in modulating atherogenic lipoproteins.

C Roger White1, Dennis I Goldberg, G M Anantharamaiah

  • 1aDepartment of Medicine, Division of Cardiovascular Disease bDivision of Gerontology, Geriatric Medicine and Palliative Care cDivision of Biochemistry and Molecular Genetics dUniversity of Alabama at Birmingham, Birmingham, Alabama eLipimetiX Development, LLC, Natick, Massachusetts, USA.

Current Opinion in Lipidology
|August 14, 2015
PubMed
Summary
This summary is machine-generated.

New drug classes are in development to lower atherogenic lipoproteins, offering hope for patients with coronary artery disease who cannot tolerate statins or have low HDL-cholesterol.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

Related Experiment Videos

Last Updated: Apr 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

12.7K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.9K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Statins and other agents lower LDL-cholesterol but have side effects and may not address residual risk from low HDL-cholesterol.
  • Previous HDL-raising therapies have yielded disappointing results.
  • Atherogenic lipoproteins contribute to coronary artery disease and other vascular diseases.

Purpose of the Study:

  • To review recent advances in pharmacotherapies for reducing atherogenic lipoproteins.
  • To discuss novel treatments for coronary artery disease and related vascular conditions.
  • To explore emerging therapies for patients with statin intolerance or low HDL-cholesterol.

Main Methods:

  • Review of recent clinical trials and ongoing research in pharmacotherapy for dyslipidemia.
  • Focus on novel drug classes targeting atherogenic lipoprotein reduction.
  • Discussion of ATP citrate lyase inhibitors, PCSK9 inhibitors, CETP inhibitors, and apolipoprotein E mimetic peptides.

Main Results:

  • Development of novel pharmacotherapies, including ATP citrate lyase and PCSK9 inhibitors, shows promise for reducing atherogenic lipoproteins.
  • Emerging HDL therapies, such as cholesteryl ester transfer protein inhibitors and apolipoprotein E mimetic peptides, are under clinical evaluation.
  • These new agents may offer alternative treatment options for patients with cardiovascular disease.

Conclusions:

  • Several new drug classes are in clinical evaluation for their potential to reduce atherogenic lipoproteins.
  • These promising therapies could benefit patients with coronary artery disease, particularly those who are statin intolerant.
  • Further research is needed to establish the efficacy and safety of these novel treatments.